Geoffrey C. Hsu, partner of OrbiMed and manager of the BiotechGrowth trust, assesses the key drivers for the sector in 2016 and beyond.
The era of 'Big Pharma' is over and companies are transitioning to more complex biological products, explains Tim Crockford from Hermes Sourcecap.